SEC Form 4	
------------	--

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OWB APPRO	JVAL
OMB Number:	3235-0287
Estimated average burg	len

hours per response:	0.5
Estimated average burden	

1. Name and Address of Reporting Person* BRIMBLECOMBE ROGER W				2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]							tionship of Reporting all applicable) Director	10% C	Owner	
INCORPORATE	St) (First) (Middle)   O VERTEX PHARMACEUTICALS 3. Date of Earliest Transaction (Month/Day/Year)   04/10/2007									Officer (give title below)	Other below)	(specify		
130 WAVERLY STREET					endment, Date of (	Driginal	Filed	(Month/Day/Ye	6. Indiv Line)	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) CAMBRIDGE	MA	02139									Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)												
	Ta	able I - No	n-Deriva	tive S	ecurities Acq	uired,	Disp	posed of, c	or Ben	eficially	Owned			
Date			2. Transact Date (Month/Day		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4				5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
						Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock			04/10/2	2007		М		10,000	A	<b>\$19.78</b>	10,000	D		
Common Stock 04/10/				2007		<b>S</b> <sup>(1)</sup>		10,000	D	\$32.36	0	D		
		<b>T</b> - 1 - 1 - 11	D			and p			D					

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deri Seci Acq (A) ( Disp of (E	umber vative urities uired or oosed 0) (Instr. and 5)	6. Date Exerci Expiration Dat (Month/Day/Ye	te	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		s Derivative Security ecurity (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$19.78	04/10/2007		А			10,000	06/01/1997 <sup>(2)</sup>	05/31/2007	Common Stock	10,000	\$0	0	D	

Explanation of Responses:

1. Transaction made pursuant to Dr. Brimblecombe's company approved trading plan established under Rule 10b5-1.

2. Right to buy under 1996 Stock and Option Plan, fully vested on grant date, 6/1/1997.

**Remarks:** 

Valerie L. Andrews, Attorney-04/11/2007

\*\* Signature of Reporting Person Date

In-Fact

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.